In a report released yesterday, Allen Klee from Maxim Group maintained a Buy rating on Marpai (MRAI – Research Report), with a price target of $6.00. The company’s shares opened today at $1.64.
Klee covers the Technology sector, focusing on stocks such as Auddia, CareCloud, and Zedge. According to TipRanks, Klee has an average return of -19.3% and a 25.27% success rate on recommended stocks.
Currently, the analyst consensus on Marpai is a Moderate Buy with an average price target of $6.00.
See the top stocks recommended by analysts >>
The company has a one-year high of $13.60 and a one-year low of $1.52. Currently, Marpai has an average volume of 148.8K.
Based on the recent corporate insider activity of 8 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of MRAI in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Marpai Inc operates as a health plan company. It offers a health plan services system that addresses the problems of healthcare past and enables companies to provide healthcare to employees.
Read More on MRAI:
- MARPAI, INC. REPORTS SECOND QUARTER 2023 RESULTS
- MRAI Upcoming Earnings Report: What to Expect?
- Marpai collaborates with Nuvoair to offer care to employer health plans
- Marpai Confirms Revenue Guidance for Q2 2023 of $9.5 Million to $9.8 Million
- Marpai still sees Q2 revenue $9.5M-$9.8M, one estimate $8.24M
